07:37 EST Regenxbio (RGNX) down 35% to $8.59 after FDA places clinical hold on RGX-111
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio announces FDA places clinical hold of RGX-111
- Regenxbio assumed with an Overweight at Barclays
- RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating
- Regenxbio highlights progress, anticipated milestones
- Regenxbio price target raised to $28 from $20 at BofA